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A B S T R A C T
Cervical intraepithelial neoplasia (CIN) can be detected in the cytologic smears years before invasive squamous can-
cer arises, but no reproducible morphologic criteria exist to predict behavior of cervical lesions. The possibility of predict-
ing the clinical course of cervical lesions could be of high value in clinical practice and some women will spare of unnec-
essary treatment. HPV L1 capsid protein represents about 90% of the total protein on the surface of the virus and can be
detected in mild to moderate dysplasia and rarely in severe dysplasia. The purpose of the study was to evaluate the use of
immunodetection of HPV L1 protein on archival Pap smears with findings of mild and moderate dysplasia in predicting
its clinical course. Immunochemical analyses with L1 antibody revealed positively stained nuclei of squamous epithelial
cells in 56 of 114 smears (49.1%). The staining results were correlated with follow-up smears or with histologic verifica-
tion. Regression (negativisation of the Pap smear for 24 months or longer) was noticed in 31 of 56 (55.4%) L1-positive
cases and in 20 of 58 (34.5%) L1-negative cases. Persistent disease occured in 13 (23.2%) L1-positive cases and in 14
(24.1%) L1-negative cases. Progressive disease occured in 12 (21.4%) L1-positive cases and in 24 (41.4%) L1-negative
cases. The difference in the clinical course between the L1-positive and L1-negative patients was statistically significant
(p=0.025). Also, the difference in the clinical course of the L1-negative staining in the under-30 and over-30 years age
group was statistically significant (p=0.04). For conclusion, our data confirm that immunostaining for HPV L1 capsid
protein could offer prognostic information about mild and moderate intraepithelial cervical squamous lesions.
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Introduction
Epidemiological studies have pointed out that human
papillomaviruses (HPV) are the main aetiological factor
for cervical cancer1. In the past 30 years, DNA of specific
HPV types has been found in almost all cervical cancer
biopsies2. Over 100 HPV types have been characterized
molecularly and 40 types are able to infect the genital
tract3. HPV can be classified by risk of causing cervical
cancer into low-risk (lr) and high-risk (hr) types4,5. HPV
16 is the most frequent and HPV 18 the second most fre-
quent hr HPV types contributing to 50-55%, and 15–20%
of invasive cervical cancer cases, respectively6. Women
with positive hr HPV DNA have an increased risk of cer-
vical cancer. Up to 59% of low grade squamous intra-
epithelial lesions (LSIL) are HPV DNA positive, but most
of this lesions regress spontaneously, due to natural his-
tory of HPV infection and host immunity, with clearence
of the viral genome within 1–2 years1,4,7.
Persistency of the hr HPV DNA infection, viral inte-
gration and morphologic progression of squamous intra-
epithelial lesions are markers of neoplastic progression
and are used for determining the patients requiring a
treatment1,8.
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Cervical intraepithelial neoplasia (CIN) can be de-
tected in the cytologic smears years before invasive squa-
mous cancer arises. Appearance of koilocytes in cervical
smears indicates the presence of the papillomavirus infe-
ction9, but no reproducible morphologic criteria exist to
predict behavior of cervical lesions. Routine molecular
genetic methods also can not be helpful, but recently de-
veloped biomarkers may be useful in the evaluation of
the biologic potential of these lesions10–12.
Because of the high regression rates of low grade
dysplastic lesions, the possibility of predicting the behav-
ior of cervical lesions could be of high value in clinical
practice10. In Germany12, and also in Croatia13, the ac-
cepted guidelines for management of cytology diagnoses
of CIN 1 and CIN 2 lesions is expectant for a certain time
of follow up with repeat smears and knowing the pro-
gression risk some women would be spared of unneces-
sary treatment.
HPV L1 capsid protein represents about 90% of the
total protein on the surface of the virus. Together with
the minor capsid L2 protein, encapsidates the viral DNA
to built new infectious viral particles which are released
in the upper epithelial layer2. HPV L1 capsid protein is a
nuclear protein that is rapidly transported into the nu-
cleus of the cell after it is synthesised in the cytoplasm.
In CIN 1 and CIN 2 lesions virus replication is evident in
the upper squamous epithelial layer5 and allows immu-
nochemical detection of infected cell nuclei14. HPV L1
capsid protein can be detected in mild to moderate dys-
plasia and rarely in severe dysplasia7. The immuno-
staining for L1 capsid protein can be performed on native
smears, Papanicolaou stained smears, monolayer slides
and histological sections.
The aim of this study was to determine weather HPV
L1 immunoreactivity could help us to discriminate be-
tween regresing and persistent/progressing mild and mo-
derate cervical dysplasia in cytological specimens. We
immunostained archival Pap smears from hr HPV DNA
positive squamous lesions with mild or moderate dys-
plasia. The staining results were correlated with fol-
low-up smears for lesions which are going to remission or
for persistent lesions with mild dysplasia. Progressive or
persistent lesions with moderate dysplasia were corre-
lated with histologic verification on Large Loop Excision
of the Transformation Zone (LLETZ) or conization.
Materials and Methods
This retrospective study has been made on archival
material and data of the Department of Gynecological
Cytology, University Department of Gynecology and
Obtetrics, Rijeka University Hospital Center, Croatia.
From January 1, 2005 till January 1, 2006 routinely
stained archival Pap smear slides from 114 lesions with
mild (85 smears) and moderate (29 smears) dysplasia
were included. Pap smears were classified according to
»The Classification of cytologic findings of cervix uteri
»Zagreb 2002« (The Modification of the »Zagreb 1990«
and »NCI Bethesda System 2001« Classifications)15. The
HPV status was assessed using the digene Hybrid Cap-
ture 2 test (hc2 High-Risk HPV DNA Test, Qiagen
Gaithersburg, USA) and all samples were positive for hr
HPV DNA.
The Pap smears were immunochemically stained us-
ing a panreactive HPV L1 antibody. L1 capsid protein is
synthesized in differentiated squamous epithelia of the
superficial layer that are easy to obtain during the smear
test. From women with remission (continued absence of
dysplastic or malignant epithelial cell changes), follow-
-up smears were available. Most of the cases of persistent
mild dysplasia were correlated with follow-up smears,
too. Histologic results of LLETZ or conization from pa-
tients with progression or persistent lesions with moder-
ate dysplasia are known. The clinical course were com-
pared for two defined groups: under-30 and over-30 years
of age.
Immunochemistry
From Papanicolaou stained slides the coverslip was
removed (slides was remained in xylene for few days). Af-
ter rehydratation, for antigen demasking, the slides were
transfer in the water bath, cover with citric buffer and
boiled for 20 minutes. Than the slides were incubated
with the anti-HPV L1 capsid protein screening antibody
(Cytoactiv screening antibody, Cytoimmun diagnostic
GmbH, Pirmasens, Germany) for 30 minutes, the detec-
tion reagent for 10 minutes and the chromogen for 5
minutes. After each step the slides were washed for 1
minute in washing buffer. Non-diluted haematoxylin was
used for counterstaining. The slides were covered with
aqueous mounting medium (Faramount Aqueous Moun-
ting Medium, DakoCytomation) and coverslipped. Posi-
tive controls from L1 positive smears provided by the
manufacturer of the L1 capsid antibody were used for
each staining series. Stained slides were studied by light
microscopy independently by two cytologist. Epithelial
cells with a clear nuclear staining were scored as posi-
tive. Staining within the cytoplasma was neglected. The
follow-up data for a dysplastic lesions were not known at
the time of slide evaluation.
Progression was defined as a citological or histological
verified upgradeing of the lesion (CIN1 to HSIL, or CIN2
to CIN3). Persistent disease was defined as persistence of
the histological grade of CIN or persistence of the abnor-
mal Pap smear for 18 months or longer. Regression was
defined as negativisation of the Pap smear for 24 months
or longer and in some cases also with negative control
Hybrid Capture II test.
Statistical analysis was performed using computer
software package »Statistica 7.1«. Data have been dicho-
tomized for statistical purposes for patients with regres-
sion versus patients with persistent disease and progres-
sion. The differences within the groups were tested using
c2-test. Significance was assumed at a p value less than
0.05.
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Results
Immunochemical analyses with L1 antibody revealed
positively stained nuclei of squamous epithelial cells in
56 of 114 smears (Table 1). We notice a well-preserved cy-
tologic features after the immunochemical staining pro-
cedure. The L1 capsid protein is a nuclear protein and L1
positive smears revealed strong, red to brown nuclear
staining. It was observed in one, few or sometimes many
nuclei of dysplastic squamous epithelial cells (Figure 1
and 2). Median age of women was 33 (range 20–70 years)
and median observation period was 26.8 months (range
4–60). Regression was noticed in 31 of 56 (55.4%) of
L1-positive cases and in 20 of 58 (34.5%) of L1-negative
cases. Persistent disease occured in 13 (23.2%) and pro-
gressive disease in 12 (21.4%) of L1 positive cases (7
CIN2, 5 CIN3). Of the 58 L1-negative cases, 14 (24.1%)
persisted and 24 (41.4%) went into progression (9 CIN2,
14 CIN3, 1CIM). The difference in the clinical course be-
tween the L1-positive and L1-negative patients was sta-
tistically significant (p=0.025) (Table 2).
Women under the age of 30 had L1-positive staining
in 29 of 59 cases (49.2%). Regression was noticed in 19
cases, persistent disease in 4 cases and progression in 6
cases. In the over-30 age group, L1 positive staining were
seen in 27 of 55 women (49.1%). The regression was ob-
served in 12 cases, persistent disease in 9, and progres-
sion in 6 cases. The difference was not statistically signif-
icant (p=0.11). However, in the group of L1-negative
staining we noticed a statistically significant difference
in the clinical course between woman under-30 age group
and over-30 age group (p=0.04). In the younger group we
noticed 14 cases of regression, 5 cases of persistent dis-
ease and 11 cases of progression. In the over-30 age
group the regression was observed in 6 cases, persistent
disease in 9 and progression in 13 cases (Table 3).
The significantly different clinical course of the L1
negative cases is present in two different age groups. We
noticed 14 cases of regression in the under-30 age group,
and only 6 in the over-30 age group. Progression was ob-
served in 16 cases in the under-30 age group and in 22
cases in the over-30 group (Figure 3).
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Fig. 1. Positive staining in a koilocytic cell, L1 capsid
immunostain, x400.
TABLE 1
TOTAL NUMBER OF L1 POSITIVE AND L1 NEGATIVE SMEARS
Total number of smears L1 positive L1 negative
114 56 (49.1%) 58 (50.9%)
TABLE 2
CLINICAL COURSE OF DISEASE FOR L1 POSITIVE AND HPV L1 NEGATIVE CASES
Clinical course L1 positive staining L1 negative staining Total
Regression 31 (55.4%) 20 (34.5%) 51
Persistent disease/ Progression 25 (44.6%) 38 (65.5%) 63
p=0.025
Fig. 2. Positive staining in groups of dyscariotic cells (LSIL),
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Fig. 3. The difference in the clinical course of the L1 negative
staining in the under-30 and over-30 age group.
Discussion
The main purporses of Pap test are early diagnosis of
cervical precancerous lesions in cervical cancer screening
programmes16, predicting grade of the lesions, as well as
follow-up after conservative surgical treatment17,18. One
major issue in the management of cervical precancerous
lesions is the evaluation of the progression risk of dys-
plastic lesions10. L1 capsid protein is synthesized in the
nucleus during the productive phase of the viral life cycle
in upper epithelial layers. Within this phase, morphologi-
cal epithelial changes occur presenting as mild or moder-
ate dysplasia in cytological smears19.
Our data demonstrate that L1 positive patients with
mild or moderate dysplastic cervical lesions have reduced
risk of disease progression, compared to L1 negative pa-
tients, because in 31 (55.4%) L1 positive patients we no-
ticed regression of the lesions. Griesser et al.14 demon-
strate regression in 69%, Rauber et al.12 in 38.7% and Lee
et al.20 in 46.1%. In L1 negative patients we noticed pro-
gression in 38 (65.5%) cases, which is similar to results of
Griesser et al.14 (76.3%), but Rauber et al.12 notice pro-
gression only in 25.9% cases. This different data may be
due to different grouping of the cases, because patients
with persistent disease some authors added to regression
and others to progression cases. Krivak Bolan~a et al.21
notice progression in 33.3% and persistent disease in
16.7% of cases. The exact cause for the significantly re-
duced or lacking L1 capsid protein synthesis in progres-
sive intraepithelial lesions, is not known. Melsheimer et
al.7 demonstrates that the expression of L1 capsid pro-
teins are significantly reduced in HPV 16 DNA positive
HSIL and HPV hr DNA positive HSIL. They thought
that explanation may be found in a disturbed viral cellu-
lar interaction and loss of L1 expression due to integra-
tion. Integration of the virus DNA into the host cell ge-
nome is detectable in some HSIL lesions, but develop-
ment of viral capsid antigen L1 also depends upon trans-
criptional factors. This factors are result of abnormal
E6/E7 gene activation and can be expressed during the
maturation process from basal to superficial epithelial
cell5. In HSIL the maturation is disturbed and predomi-
nant cell type are dysplastic basal epithelial cells with re-
duced L1 capsid protein expression. Also, control mecha-
nisms exist at the translational level (mRNA), or molecu-
lar changes in the episomal L1 gene14,19. However, de-
spite a detectable antigenic L1 capsid synthesis of the
HPV, the immune system is not capable of eliminating in-
fected host cells in rare cases19. Our data confirm that 12
cases (21.4%) of L1 positive patients went into progres-
sion, and other authors obtained similar results12,14.
HPV L1 capsid proteins are considered to be a major
target of cellular immune response in CIN. A reduction
or loss of capsid antigen production therefore might re-
sult in a reduction of cellular immune response7,20 and
promote further transformation of immature epithelial
cells5. Lack of T-cell response also leads to reduced anti-
body synthesis for protecting against endogenous and ex-
ogenous reinfection14. Griesser et al. observed that differ-
ent clinical course of L1 antigen-positive and L1-antigen
negative groups became increasingly apparent with ris-
ing age and in the age group >45, most lesions re-
gressed14. Lee and al. noticed that L1 antigen-negative
rate was higher than the positive rate in the over-40 age
group and conclude that increased L1 capsid negative
rate might reflect the increasing prevalence of cervical
cancer in the old age group20. Our data demonstrate that
progression is significantly more often observed in over-
-30 age group comparing to under-30 age group in the L1
antigen-negative cases.
We can conclude, that under-30 years age patients
with mild and moderate dysplastic lesions and L1 anti-
gen-positive smears have low risk for disease progression
and watch-and-wait management with regular control
smears is optimal. If over-30 age patients with persistent
mild or moderate dysplasia have L1 antigen-negative
smears and are hr HPV positive, short-terms controls
and histological verification is justified. Large prospec-
tive follow-up studies is needed to confirm the prognostic
value of L1 protein.
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VRIJEDNOST HPV L1 PROTEINA U PROGNOZI BLAGE I UMJERENE DISPLAZIJE
VRATA MATERNICE
S A @ E T A K
Cervikalna intraepitelna neoplazija (CIN) mo`e se dijagnosticirati u citolo{kim razmazima godinama prije nastanka
invazivnog karcinoma, ali ne postoje morfolo{ki kriteriji koji bi ukazivali na prognozu takve promjene. Mogu}nost
predvi|anja klini~kog tijeka bolesti va`na je u klini~koj praksi i neke bi `ene po{tedjela nepotrebnih kirur{kih zahvata.
Ekspresija HPV L1 proteina na|ena je kod blage i umjerene displazije, a rijetko kod te{ke displazije. Cilj rada je pro-
cjena vrijednosti imunocitokemijskog bojenja HPV L1 proteina u predvi|anju klini~kog tijeka bolesti. Kori{teni su ar-
hivski Papa razmazi s nalazom blage i umjerene displazije. Imunocitokemijska analiza pokazala je pozitivnu reakciju
kod 56 od 114 uzoraka (49,1%). Usporedbom rezultata bojenja s kontrolnim citolo{kim razmazima ili patohistolo{kom
potvrdom, regresija (normalizacija Papa razmaza tijekom 24 mjeseca ili dulje) je na|ena kod 31 od 56 (55,4%) L1-
-pozitivnih razmaza, te kod 20 od 58 (34,5%) L1-negativnih razmaza. Stagnacija bolesti uo~ena je kod 13 (23,2%) L1-po-
zitivnih razmaza i kod 14 (24,1%) L1-negativnih razmaza. Progresija bolesti na|ena je kod 12 (21,4%) L1-pozitivnih
razmaza i 24 (41,4%) L1-negativnih razmaza. Razlika u klini~kom tijeku bolesti izme|u L1-pozitivnih i L1-negativnih
pacijentica je statisti~ki zna~ajna (p=0,025). Tako|er, razlika u klini~kom tijeku bolesti L1-negativnih pacijentica mla-
|ih od 30 i starijih od 30 godina je statisti~ki zna~ajna (p=0,04). Na{i rezultati ukazuju da imunocitokemijsko bojenje
HPV L1 proteina mo`e ukazati na prognozu blage i umjerene displazije vrata maternice.
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